跳至主要内容
临床试验/NCT00184665
NCT00184665已完成3 期

2 Year Efficiency and Safety Comparison of Insulin Detemir and NPH Insulin in Type 1 Diabetes.

Novo Nordisk A/S29 个研究点 分布在 10 个国家目标入组 501 人开始时间: 2004年6月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
501
试验地点
29
主要终点
HbA1c

研究概览

简要总结

This trial is conducted in Africa, Asia, Europe, Oceania, and South America. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir compared to NPH insulin administered as basal insulin for the treatment of type 1 diabetes and to verify the safety of use (number and severity of episodes of hypoglycemia, body weight, and insulin antibodies and side effects).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Type 1 diabetes
  • •Currently on basal-bolus regimen
  • •BMI = 35.0 kg/m2
  • •HbA1c =11.0%

排除标准

  • •Proliferative retinopathy or maculopathy
  • •Recurrent major hypoglycaemia
  • •Cardial problems
  • •Uncontrolled hypertension
  • •Impaired hepatic or renal function

结局指标

主要结局

HbA1c

时间窗: after a two-year trial period

次要结局

  • Blood glucose
  • Body composition
  • Body weight
  • Antibodies
  • Adverse events
  • Hypoglycaemia

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (29)

Loading locations...

相似试验